Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Assessing the impact of a research funder's recommendation to consider core outcome sets.

Hughes KL, Kirkham JJ, Clarke M, Williamson PR.

PLoS One. 2019 Sep 13;14(9):e0222418. doi: 10.1371/journal.pone.0222418. eCollection 2019.

PMID:
31518375
2.

Protocols for the Analysis of microRNA Expression, Biogenesis, and Function in Immune Cells.

Zhang N, Hu G, Myers TG, Williamson PR.

Curr Protoc Immunol. 2019 Sep;126(1):e78. doi: 10.1002/cpim.78.

PMID:
31483103
3.

Intradural cauda equina Candida abscess presenting with hydrocephalus: case report.

Argersinger DP, Natkha VP, Shepard MJ, Thomas AA, Oler AJ, Williamson PR, Chittiboina P, Heiss JD.

J Neurosurg Spine. 2019 Aug 30:1-4. doi: 10.3171/2019.6.SPINE19271. [Epub ahead of print]

PMID:
31470401
4.

Improving therapy of severe infections through drug repurposing of synergistic combinations.

Cheng YS, Williamson PR, Zheng W.

Curr Opin Pharmacol. 2019 Aug 24;48:92-98. doi: 10.1016/j.coph.2019.07.006. [Epub ahead of print] Review.

PMID:
31454708
5.

Industry funding was associated with increased use of core outcome sets.

Kirkham JJ, Bracken M, Hind L, Pennington K, Clarke M, Williamson PR.

J Clin Epidemiol. 2019 Jul 18;115:90-97. doi: 10.1016/j.jclinepi.2019.07.007. [Epub ahead of print]

PMID:
31326541
6.

Audiologic and Otologic Complications of Cryptococcal Meningoencephalitis in Non-HIV Previously Healthy Patients.

King KA, Ansari G, Panackal AA, Zalewski C, Anjum S, Bennett JE, Beri A, Kim HJ, Hammoud D, Brewer CC, Williamson PR.

Otol Neurotol. 2019 Jul;40(6):e657-e664. doi: 10.1097/MAO.0000000000002242.

PMID:
31157723
7.

Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis.

Lu R, Hollingsworth C, Qiu J, Wang A, Hughes E, Xin X, Konrath KM, Elsegeiny W, Park YD, Atakulu L, Craft JC, Tramont EC, Mannino R, Williamson PR.

MBio. 2019 May 28;10(3). pii: e00724-19. doi: 10.1128/mBio.00724-19.

8.

Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial.

Lewis GA, Schelbert EB, Naish JH, Bedson E, Dodd S, Eccleson H, Clayton D, Jimenez BD, McDonagh T, Williams SG, Cooper A, Cunnington C, Ahmed FZ, Viswesvaraiah R, Russell S, Neubauer S, Williamson PR, Miller CA.

Cardiovasc Drugs Ther. 2019 Aug;33(4):461-470. doi: 10.1007/s10557-019-06876-y.

9.

Protocol for the development of a core outcome set for cauda equina syndrome: systematic literature review, qualitative interviews, Delphi survey and consensus meeting.

Srikandarajah N, Noble AJ, Wilby M, Clark S, Williamson PR, Marson AG.

BMJ Open. 2019 May 1;9(4):e024002. doi: 10.1136/bmjopen-2018-024002.

10.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.

Klokker L, Berthelsen DB, Woodworth T, Andersen KM, Furst DE, Devoe D, Williamson PR, Suarez-Almazor ME, Strand V, Leong AL, Goel N, Boers M, Brooks PM, March L, Sloan VS, Tugwell P, Simon LS, Christensen R.

J Rheumatol. 2019 Sep;46(9):1173-1178. doi: 10.3899/jrheum.190196. Epub 2019 May 1.

PMID:
31043547
11.

Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.

Ramanan AV, Dick AD, Jones AP, Hughes DA, McKay A, Rosala-Hallas A, Williamson PR, Hardwick B, Hickey H, Rainford N, Hickey G, Kolamunnage-Dona R, Culeddu G, Plumpton C, Wood E, Compeyrot-Lacassagne S, Woo P, Edelsten C, Beresford MW.

Health Technol Assess. 2019 Apr;23(15):1-140. doi: 10.3310/hta23150.

12.

Improvement was needed in the standards of development for cancer core outcome sets.

Gargon E, Williamson PR, Blazeby JM, Kirkham JJ.

J Clin Epidemiol. 2019 Aug;112:36-44. doi: 10.1016/j.jclinepi.2019.04.006. Epub 2019 Apr 19.

13.

What is important to people living with dementia?: the 'long-list' of outcome items in the development of a core outcome set for use in the evaluation of non-pharmacological community-based health and social care interventions.

Harding AJE, Morbey H, Ahmed F, Opdebeeck C, Lasrado R, Williamson PR, Swarbrick C, Leroi I, Challis D, Hellstrom I, Burns A, Keady J, Reilly ST.

BMC Geriatr. 2019 Mar 27;19(1):94. doi: 10.1186/s12877-019-1103-5.

14.

Incorporating patients' perspectives into the initial stages of core outcome set development: a rapid review of qualitative studies of type 2 diabetes.

Gorst SL, Young B, Williamson PR, Wilding JPH, Harman NL.

BMJ Open Diabetes Res Care. 2019 Feb 28;7(1):e000615. doi: 10.1136/bmjdrc-2018-000615. eCollection 2019. Review.

15.

The Pat1-Lsm complex prevents 3' to 5' degradation of a specific subset of ATG mRNAs during nitrogen starvation-induced autophagy.

Gatica D, Hu G, Zhang N, Williamson PR, Klionsky DJ.

Autophagy. 2019 Apr;15(4):750-751. doi: 10.1080/15548627.2019.1587262. Epub 2019 Mar 18.

PMID:
30885034
16.

A Multicenter, Longitudinal Cohort Study of Cryptococcosis in HIV-Negative People in the United States.

Marr KA, Sun Y, Spec A, Lu N, Panackal A, Bennett J, Pappas P, Ostrander D, Datta K, Zhang SX, Williamson PR; Cryptococcus Infection Network Cohort (CINCH) Study Working Group.

Clin Infect Dis. 2019 Mar 11. pii: ciz193. doi: 10.1093/cid/ciz193. [Epub ahead of print]

PMID:
30855688
17.

Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT).

Butcher NJ, Monsour A, Mew EJ, Szatmari P, Pierro A, Kelly LE, Farid-Kapadia M, Chee-A-Tow A, Saeed L, Monga S, Ungar W, Terwee CB, Vohra S, Fergusson D, Askie LM, Williamson PR, Chan AW, Moher D, Offringa M.

Trials. 2019 Mar 6;20(1):161. doi: 10.1186/s13063-019-3248-0.

18.

Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017.

Smith TO, Mansfield M, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Aug;46(8):976-980. doi: 10.3899/jrheum.181066. Epub 2019 Mar 1.

PMID:
30824657
19.

Core Outcome Set-STAndardised Protocol Items: the COS-STAP Statement.

Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR; COS-STAP Group.

Trials. 2019 Feb 11;20(1):116. doi: 10.1186/s13063-019-3230-x.

20.

The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis.

Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Dodd S, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Aug;46(8):981-989. doi: 10.3899/jrheum.181194. Epub 2019 Jan 15.

PMID:
30647185
21.

Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study.

Potter S, Conroy EJ, Cutress RI, Williamson PR, Whisker L, Thrush S, Skillman J, Barnes NLP, Mylvaganam S, Teasdale E, Jain A, Gardiner MD, Blazeby JM, Holcombe C; iBRA Steering Group; Breast Reconstruction Research Collaborative.

Lancet Oncol. 2019 Feb;20(2):254-266. doi: 10.1016/S1470-2045(18)30781-2. Epub 2019 Jan 9.

22.

Involving people living with dementia in research: an accessible modified Delphi survey for core outcome set development.

Morbey H, Harding AJE, Swarbrick C, Ahmed F, Elvish R, Keady J, Williamson PR, Reilly ST.

Trials. 2019 Jan 6;20(1):12. doi: 10.1186/s13063-018-3069-6.

23.

Choosing important health outcomes for comparative effectiveness research: 4th annual update to a systematic review of core outcome sets for research.

Gargon E, Gorst SL, Harman NL, Smith V, Matvienko-Sikar K, Williamson PR.

PLoS One. 2018 Dec 28;13(12):e0209869. doi: 10.1371/journal.pone.0209869. eCollection 2018.

24.

Cryptococcal meningitis is a cause for cross-reactivity in cerebrospinal fluid assays for anti-Histoplasma, anti-Coccidioides and anti-Blastomyces antibodies.

Bahr NC, Panackal AA, Durkin MM, Smedema ML, Keown W, Davis TE, Raymond-Guillen L, Park YD, Marr KA, Fries BC, Williamson PR, Boulware DR, Wheat LJ.

Mycoses. 2019 Mar;62(3):268-273. doi: 10.1111/myc.12882. Epub 2019 Jan 1.

PMID:
30565753
25.

Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence.

Park YD, Jarvis JN, Hu G, Davis SE, Qiu J, Zhang N, Hollingsworth C, Loyse A, Gardina PJ, Valyi-Nagy T, Myers TG, Harrison TS, Bicanic T, Williamson PR.

MBio. 2018 Dec 18;9(6). pii: e02353-18. doi: 10.1128/mBio.02353-18.

26.

Higher number of items associated with significantly lower response rates in COS Delphi surveys.

Gargon E, Crew R, Burnside G, Williamson PR.

J Clin Epidemiol. 2019 Apr;108:110-120. doi: 10.1016/j.jclinepi.2018.12.010. Epub 2018 Dec 15.

27.

The Pat1-Lsm Complex Stabilizes ATG mRNA during Nitrogen Starvation-Induced Autophagy.

Gatica D, Hu G, Liu X, Zhang N, Williamson PR, Klionsky DJ.

Mol Cell. 2019 Jan 17;73(2):314-324.e4. doi: 10.1016/j.molcel.2018.11.002. Epub 2018 Dec 6.

PMID:
30527663
28.

A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus.

Fish R, Sanders C, Adams R, Brewer J, Brookes ST, DeNardo J, Kochhar R, Saunders MP, Sebag-Montefiore D, Williamson PR, Renehan AG.

Lancet Gastroenterol Hepatol. 2018 Dec;3(12):865-873. doi: 10.1016/S2468-1253(18)30264-4. Review.

29.

Reducing attrition within clinical trials: The communication of retention and withdrawal within patient information leaflets.

Kearney A, Rosala-Hallas A, Bacon N, Daykin A, Shaw ARG, Lane AJ, Blazeby JM, Clarke M, Williamson PR, Gamble C.

PLoS One. 2018 Oct 31;13(10):e0204886. doi: 10.1371/journal.pone.0204886. eCollection 2018.

30.

Reporting of outcomes in gastric cancer surgery trials: a systematic review.

Alkhaffaf B, Blazeby JM, Williamson PR, Bruce IA, Glenny AM.

BMJ Open. 2018 Oct 17;8(10):e021796. doi: 10.1136/bmjopen-2018-021796.

31.

Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.

Hughes DA, Culeddu G, Plumpton CO, Wood E, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot Lacassagne S, Hardwick B, Hickey H, Woo P, Beresford MW, Ramanan AV.

Ophthalmology. 2019 Mar;126(3):415-424. doi: 10.1016/j.ophtha.2018.09.043. Epub 2018 Oct 16.

PMID:
30336181
32.

Development of a standardised set of metrics for monitoring site performance in multicentre randomised trials: a Delphi study.

Whitham D, Turzanski J, Bradshaw L, Clarke M, Culliford L, Duley L, Shaw L, Skea Z, Treweek SP, Walker K, Williamson PR, Montgomery AA; Site Performance Metrics for Multicentre Randomised Trials Collaboration.

Trials. 2018 Oct 16;19(1):557. doi: 10.1186/s13063-018-2940-9.

33.

"Real-Time" High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report.

Sun W, Hesse S, Xu M, Childs RW, Zheng W, Williamson PR.

Front Med (Lausanne). 2018 Sep 20;5:267. doi: 10.3389/fmed.2018.00267. eCollection 2018.

34.

Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews.

Kirkham JJ, Altman DG, Chan AW, Gamble C, Dwan KM, Williamson PR.

BMJ. 2018 Sep 28;362:k3802. doi: 10.1136/bmj.k3802. No abstract available.

35.

Development of an online resource for recruitment research in clinical trials to organise and map current literature.

Kearney A, Harman NL, Rosala-Hallas A, Beecher C, Blazeby JM, Bower P, Clarke M, Cragg W, Duane S, Gardner H, Healy P, Maguire L, Mills N, Rooshenas L, Rowlands C, Treweek S, Vellinga A, Williamson PR, Gamble C.

Clin Trials. 2018 Dec;15(6):533-542. doi: 10.1177/1740774518796156. Epub 2018 Aug 31.

36.

Epigenetic Regulation of Autophagy: A Path to the Control of Autoimmunity.

Hargarten JC, Williamson PR.

Front Immunol. 2018 Aug 14;9:1864. doi: 10.3389/fimmu.2018.01864. eCollection 2018. Review.

37.

Correction to: Survey indicated that core outcome set development is increasingly including patients, being conducted internationally and using Delphi surveys.

Biggane AM, Brading L, Ravaud P, Young B, Williamson PR.

Trials. 2018 Aug 8;19(1):430. doi: 10.1186/s13063-018-2595-6.

38.

Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set.

Harman NL, Wilding J, Curry D, Harris J, Logue J, Pemberton RJ, Perreault L, Thompson G, Tunis S, Williamson PR; SCORE-IT study team.

Trials. 2018 Aug 7;19(1):427. doi: 10.1186/s13063-018-2805-2.

39.

Time-dependent efficacy of longitudinal biomarker for clinical endpoint.

Kolamunnage-Dona R, Williamson PR.

Stat Methods Med Res. 2018 Jun;27(6):1909-1924. doi: 10.1177/0962280216673084. Epub 2016 Oct 17.

PMID:
29767590
40.

TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries.

Gerbens LAA, Apfelbacher CJ, Irvine AD, Barbarot S, de Booij RJ, Boyce AE, Deleuran M, Eichenfield LF, Hof MH, Middelkamp-Hup MA, Roberts A, Schmitt J, Vestergaard C, Wall D, Weidinger S, Williamson PR, Flohr C, Spuls PI; international TREAT Registry Taskforce.

Br J Dermatol. 2019 Apr;180(4):790-801. doi: 10.1111/bjd.16714. Epub 2018 Aug 3.

PMID:
29761486
41.

Immunology of Cryptococcal Infections: Developing a Rational Approach to Patient Therapy.

Elsegeiny W, Marr KA, Williamson PR.

Front Immunol. 2018 Apr 4;9:651. doi: 10.3389/fimmu.2018.00651. eCollection 2018. Review.

42.

Quality Measurement Recommendations Relevant to Clinical Guidelines in Germany and the United Kingdom: (What) Can We Learn From Each Other?

Petzold T, Deckert S, Williamson PR, Schmitt J.

Inquiry. 2018 Jan-Dec;55:46958018761495. doi: 10.1177/0046958018761495.

43.

Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).

Fish R, Sanders C, Ryan N, der Veer SV, Renehan AG, Williamson PR.

Colorectal Dis. 2018 May;20(5):371-382. doi: 10.1111/codi.14103. Epub 2018 Apr 17.

44.

Identifying trial recruitment uncertainties using a James Lind Alliance Priority Setting Partnership - the PRioRiTy (Prioritising Recruitment in Randomised Trials) study.

Healy P, Galvin S, Williamson PR, Treweek S, Whiting C, Maeso B, Bray C, Brocklehurst P, Moloney MC, Douiri A, Gamble C, Gardner HR, Mitchell D, Stewart D, Jordan J, O'Donnell M, Clarke M, Pavitt SH, Guegan EW, Blatch-Jones A, Smith V, Reay H, Devane D.

Trials. 2018 Mar 1;19(1):147. doi: 10.1186/s13063-018-2544-4.

45.

Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)?

Treweek S, Bevan S, Bower P, Campbell M, Christie J, Clarke M, Collett C, Cotton S, Devane D, El Feky A, Flemyng E, Galvin S, Gardner H, Gillies K, Jansen J, Littleford R, Parker A, Ramsay C, Restrup L, Sullivan F, Torgerson D, Tremain L, Westmore M, Williamson PR.

Trials. 2018 Feb 23;19(1):139. doi: 10.1186/s13063-018-2535-5.

46.

Adherence to best practice consensus guidelines for implant-based breast reconstruction: Results from the iBRA national practice questionnaire survey.

Mylvaganam S, Conroy EJ, Williamson PR, Barnes NLP, Cutress RI, Gardiner MD, Jain A, Skillman JM, Thrush S, Whisker LJ, Blazeby JM, Potter S, Holcombe C; iBRA Steering Group; Breast Reconstruction Research Collaborative.

Eur J Surg Oncol. 2018 May;44(5):708-716. doi: 10.1016/j.ejso.2018.01.098. Epub 2018 Feb 7.

47.

Survey indicated that core outcome set development is increasingly including patients, being conducted internationally and using Delphi surveys.

Biggane AM, Brading L, Ravaud P, Young B, Williamson PR.

Trials. 2018 Feb 17;19(1):113. doi: 10.1186/s13063-018-2493-y. Erratum in: Trials. 2018 Aug 8;19(1):430.

48.

Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries.

Davis K, Gorst SL, Harman N, Smith V, Gargon E, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR.

PLoS One. 2018 Feb 13;13(2):e0190695. doi: 10.1371/journal.pone.0190695. eCollection 2018. Review.

49.

Global health trials methodological research agenda: results from a priority setting exercise.

Rosala-Hallas A, Bhangu A, Blazeby J, Bowman L, Clarke M, Lang T, Nasser M, Siegfried N, Soares-Weiser K, Sydes MR, Wang D, Zhang J, Williamson PR.

Trials. 2018 Feb 5;19(1):48. doi: 10.1186/s13063-018-2440-y.

50.

High rates of cerebral toxoplasmosis in HIV patients presenting with meningitis in Accra, Ghana.

Opintan JA, Awadzi BK, Biney IJK, Ganu V, Doe R, Kenu E, Adu RF, Osei MM, Akumwena A, Grigg ME, Fahle GA, Newman MJ, Williamson PR, Lartey M.

Trans R Soc Trop Med Hyg. 2017 Oct 1;111(10):464-471. doi: 10.1093/trstmh/trx083.

Supplemental Content

Loading ...
Support Center